The Korea Herald reports that Archigen Biotech, a joint venture between AstraZeneca UK and Samsung BioLogics, has applied for FDA approval to begin Phase I clinical trials for its rituximab biosimilar, SAIT101.
Archigen Biotech’s website states that clinical trials for SAIT101 are expected to begin globally in Q3 of 2016.
The post Archigen Biotech seeks FDA Approval for Rituximab Phase I Clinical Trials appeared first on Big Molecule Watch.